A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

By Jack Phillips Contributing Writer A study published this week suggests that a common sleeping medication, zolpidem, may ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Frontotemporal dementia (FTD) is a rare and progressive form of dementia that primarily affects people between the ages of 40 ...

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in a adults with Parkinson’s disease whose ...

With an aging global population, rates of Alzheimer’s disease on the rise, high costs of care for those with dementia, and an unpromising landscape for effective drugs, questions of how to prevent or ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...